Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales

24 Mar 2022

Abstract excerpt

Transgenic human monoclonal antibodies derived from humanized mice against different epitopes of the Middle East respiratory syndrome coronavirus (MERS-CoV), and chimeric llama-human bispecific heavy chain-only antibodies targeting the Rift Valley fever virus (RVFV), were produced using a CHO-based transient expression system. Two lead candidates were assessed for each model virus before selecting and progressing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35323099
DOI: 10.1080/19420862.2022.2052228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scalesPMID 35323099Read ↗

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read ↗

A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigensSemantic proximity Read ↗

Evaluation of different vector design strategies for the expression of recombinant monoclonal antibody in CHO cellsSemantic proximity Read ↗

Development of a high cell density transient CHO platform yielding mAb titers greater than 2 g/L in only 7 daysSemantic proximity Read ↗

A pipeline for the production of antibody fragments for structural studies using transient expression in HEK 293T cellsSemantic proximity Read ↗

Sequencing, cloning and expression of the panfilovirus glycoprotein specific recombinant mAb 8C12F11 in a CHO mammalian cell lineSemantic proximity Read ↗

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read ↗

Baculovirus-free insect cell expression system for high yield antibody and antigen productionSemantic proximity Read ↗

Techno-Economic Assessment of Cell-Free Synthesis of Monoclonal Antibodies Using CHO Cell ExtractsSemantic proximity Read ↗

Gene copy number, gene configuration and LC / HC mRNA ratio impact on antibody productivity and product quality in targeted integration CHO cell linesSemantic proximity Read ↗

Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectorsSemantic proximity Read ↗

Development of a CHO-Based Cell-Free Platform for Synthesis of Active Monoclonal AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.